Back in January at the J.P. Morgan Healthcare Conference, the mood across biopharma felt notably different than it did a year earlier. Conversations were more constructive. M&A and investment activity was beginning to return. Companies that had spent much of 2025 in defensive mode were once again talking about growth, partnerships, pipeline expansion, and strategic acquisitions.
Over the past several months, that optimism has largely held. We continue to see stronger deal activity, renewed investor interest, and more willingness from organizations to move programs forward. Compared to this time last year, there is noticeably more momentum across the industry. In many conversations I’ve had recently with clients and biotech and pharma executives at industry events, the sentiment remains positive overall.
But at the same time, there are more things starting to creep in.
No End to Uncertainty
The recent FDA leadership changes have added another variable to an already complex operating environment. Regardless of individual opinions about the former commissioner, leadership transitions at the FDA inevitably create questions for the industry. Organizations are now evaluating what this could mean for approval timelines, regulatory priorities, agency operations, and the overall direction of the FDA in the months ahead.
And the FDA changes are only one part of a broader picture. Executives are navigating continued pressure around drug pricing, including Most Favored Nation (MFN) and Inflation Reduction Act implications. Global conflict and tariff concerns continue to affect supply chains and operating costs. Consider rising petroleum costs, which affect everything from raw materials to transportation.
Individually, none of these issues necessarily changes the industry’s long-term outlook. Collectively, though, they create an environment where organizations need to be prepared for more volatility.
What makes this moment particularly interesting is that the underlying market fundamentals still appear relatively healthy. Products continue moving through regulatory review. M&A activity remains active. Funding conditions, while still selective, are improving compared to last year. There is still real optimism in the market. But optimism is coming with more caution attached to it.
Blocking and Tackling Will Win the Game
In my view, that makes operational discipline even more important. In periods of uncertainty, strong execution becomes a differentiator. Organizations that understand their portfolios clearly, actively manage risk, and maintain flexibility in their operating plans are better positioned to respond when conditions shift unexpectedly.
For biopharma leaders, this is a good time to revisit some fundamentals:
- Reassess portfolio priorities and investment assumptions
- Pressure-test timelines and operational dependencies
- Strengthen risk management and contingency planning
- Ensure cross-functional alignment between regulatory, clinical, manufacturing, and commercial teams
- Build flexibility into development and launch plans wherever possible
The biopharma industry has always operated in an environment where change is constant. That is not new. The companies that navigate uncertainty best are rarely the ones that predict every disruption correctly. More often, they are the organizations that build resilient operating models, maintain visibility across programs, and can adapt quickly as conditions evolve.
May 21, 2026
